Clinical Trial: An Exploratory Study Evaluating the Impact of a Reduced Starting Dose Combined with Prophylactic Management on the Tolerability and Efficacy of Neratinib as Adjuvant Intensive Therapy in Patients with HER2-Positive Breast Cancer (China)

China, Aug. 11 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'An Exploratory Study Evaluating the Impact of a Reduced Starting Dose Combined with Prophylactic Management on the Tolerability and Efficacy of Neratinib as Adjuvant Intensive Therapy in Patients with HER2-Positive Breast Cancer'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600129511

Registration Time: 2026/08/05

Type: Interventional study

Primary Sponsor: Xinyang Central Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=336838

Published by HT Digital Content Services with permission from Health Daily Digest....